These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 11464468)

  • 1. [Pathophysiology and prevention of cardiogenic brain embolism].
    Minematsu K
    Rinsho Shinkeigaku; 2000 Dec; 40(12):1244-6. PubMed ID: 11464468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose warfarin in atrial fibrillation leads to more thromboembolic events without reducing major bleeding when compared to adjusted-dose--a meta-analysis.
    Perret-Guillaume C; Wahl DG
    Thromb Haemost; 2004 Feb; 91(2):394-402. PubMed ID: 14961170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevention of brain infarction in patients with atrial fibrillation].
    Ogata T; Yasaka M
    Brain Nerve; 2007 Jan; 59(1):53-8. PubMed ID: 17354379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevention of brain infarction in patients with atrial fibrillation].
    Ogata T; Yasaka M
    No To Shinkei; 2007 Jan; 59(1):53-8. PubMed ID: 17228779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulants for nonvalvular atrial fibrillation (NVAF)--drug review.
    Cundiff DK
    MedGenMed; 2003 Feb; 5(1):4. PubMed ID: 12827065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atherothrombotic ischemic stroke in patients with atrial fibrillation.
    Benbir G; Uluduz D; Ince B; Bozluolcay M
    Clin Neurol Neurosurg; 2007 Jul; 109(6):485-90. PubMed ID: 17467891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
    Albers GW;
    Am J Manag Care; 2004 Dec; 10(14 Suppl):S462-9; discussion S469-73. PubMed ID: 15696910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal.
    Odén A; Fahlén M; Hart RG
    Thromb Res; 2006; 117(5):493-9. PubMed ID: 16517250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.
    White HD; Gruber M; Feyzi J; Kaatz S; Tse HF; Husted S; Albers GW
    Arch Intern Med; 2007 Feb; 167(3):239-45. PubMed ID: 17296878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Primary prevention of thrombosis for patients with atrial fibrillation].
    Hori M
    Rinsho Shinkeigaku; 2004 Nov; 44(11):752-5. PubMed ID: 15651282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for bleeding during anticoagulation of atrial fibrillation in older and younger patients in clinical practice.
    Abdelhafiz AH; Wheeldon NM
    Am J Geriatr Pharmacother; 2008 Mar; 6(1):1-11. PubMed ID: 18396243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Primary and secondary prevention of cardiogenic cerebral embolism].
    Hori M
    No To Shinkei; 2006 Oct; 58(10):843-8. PubMed ID: 17087275
    [No Abstract]   [Full Text] [Related]  

  • 13. [The questionnaire survey to clarify correspondence of medical doctors and dentists in Fukuoka City, Japan, for warfarin therapy at the dental extraction].
    Yasaka M; Okada Y; Inoue T; Yoshikawa H; Saku M
    No To Shinkei; 2006 Oct; 58(10):857-63. PubMed ID: 17087277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accumulation of risk factors enhances the prothrombotic state in atrial fibrillation.
    Ohara K; Inoue H; Nozawa T; Hirai T; Iwasa A; Okumura K; Lee JD; Shimizu A; Hayano M; Yano K
    Int J Cardiol; 2008 Jun; 126(3):316-21. PubMed ID: 17689760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cardioembolic infarction: clinical course and characteristics].
    Santos-Lasaosa S; Navas I; Mostacero E; López del Val J; Tejero C; Escalza I
    Rev Neurol; 2000 Dec 16-31; 31(12):1154-8. PubMed ID: 11205549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study.
    Pérez-Gómez F; Alegría E; Berjón J; Iriarte JA; Zumalde J; Salvador A; Mataix L;
    J Am Coll Cardiol; 2004 Oct; 44(8):1557-66. PubMed ID: 15489085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
    Halperin JL;
    Am Heart J; 2003 Sep; 146(3):431-8. PubMed ID: 12947359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
    Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L
    Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cardioembolic stroke: epidemiology].
    Díaz Guzmán J
    Neurologia; 2012 Mar; 27 Suppl 1():4-9. PubMed ID: 22682204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
    Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.